Benzinga | Feb 4, 2021 07:17AM EST

ADC Therapeutics Completes Enrollment In Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine (Cami) In Relapsed Or Refractory Hodgkin Lymphoma

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced completion of enrollment in the pivotal Phase 2 clinical trial evaluating the efficacy and safety of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma. A total of 117 patients have been enrolled in the trial.